info@seagull-health.com
SeagullHealth
search
Emicizumab(Hemlibra)
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
Hemlibra(Emicizumab) Instructions:Uses,Dosage, Side Effects
HEMLIBRA is a bispecific monoclonal antibody used for prophylactic treatment in hemophilia A patients.
Introduction to HEMLIBRA
HEMLIBRA (emicizumab-kxwh) is a subcutaneous injection designed to prevent bleeding episodes in patients with hemophilia A, with or without factor VIII inhibitors. It works by bridging factor IXa and factor X to restore clotting function. Available in multiple dosage strengths, it offers flexible dosing regimens for long-term management.
HEMLIBRA is indicated for routine prophylaxis in adult and pediatric patients (newborn and older) with congenital hemophilia A (Factor VIII deficiency), regardless of inhibitor status.
1. Loading Dose: 3 mg/kg subcutaneously once weekly for the first 4 weeks.
2. Maintenance Dose: Choose one of the following regimens:
1.5 mg/kg once weekly, or
3 mg/kg once every two weeks, or
6 mg/kg once every four weeks.
3. Discontinue prophylactic bypassing agents one day prior to initiating HEMLIBRA.
4. Factor VIII prophylaxis may be continued during the first week of HEMLIBRA therapy.
- Core products
- Antitumor drugs
- General drug
- Antiviral drugs
- Biological agents
- mailbox：info@lucius.la
